5AM Ventures VI, L.P. → Enliven Therapeutics, Inc. ELVN

Stake: — Shares: —

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 25/100

Passive Schedule 13G filer baseline
Held by 1 tracked 13F institutional manager
Elevated short days-to-cover (7.5 DTC)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

7 13D/G filings on this issuer

6 other filings besides this one

Filer Track Record

4 filings by this filer

3 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 7.45

9,331,398 shares short · -9.9% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $23.17M

Point72 Asset Mgmt

Other 13D/G Filings on Enliven Therapeutics, Inc.

Filed	Form	Filer	Stake	Shares
2026-06-24	SCHEDULE 13D/A	ORBIMED ADVISORS LLC	—	6,774,507	view →
2026-06-17	SCHEDULE 13D/A	ORBIMED ADVISORS LLC	10.93%	7,634,630	view →
2022-05-24	SC	New Enterprise Associates 14, L.P.	—	—	view →
2022-01-10	SC	New Enterprise Associates 14, L.P.	—	—	view →
2021-07-20	SC	Arix Bioscience plc	—	—	view →
2021-01-08	SC	Arix Bioscience plc	—	—	view →

Other Filings by 5AM Ventures VI, L.P.

Filed	Form	Issuer	Stake	Shares
2026-08-31	SCHEDULE 13D/A	CAMP4 THERAPEUTICS CORPORATION	9.90%	2,033,270	view →
2026-08-05	SCHEDULE 13D/A	CAMP4 THERAPEUTICS CORPORATION	9.90%	2,625,145	view →
2023-02-28	SC	CinCor Pharma, Inc.	—	—	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →